Browsing articles in "Psychotic Disorders"


New Long-Acting Injectable Formulation of Aripiprazole Approved
July 16, 2018   

The FDA has now approved a NanoCrystal® injectable formulation of the atypical antipsychotic aripiprazole (Alkermes' Aristada Initio) for the treatment of schizophrenia in adults...
 Continue reading (Members only)
Placental Biology and Genetic Risk for Schizophrenia
June 18, 2018   

In a recent study, the relationship between placenta biology and genetic risk for schizophrenia in the presence of early-life complications (ELCs) was examined...
 Continue reading (Members only)
2018 APA Highlight: Immunotherapies in Schizophrenia and Bipolar Disorder
May 5, 2018   

During the 2018 American Psychiatric Association (APA) Annual Meeting, Dr. Mark Weiser discussed the latest therapies being investigated to treat inflammation in schizophrenia and bipolar disorder...
 Continue reading
Updated Recommendations For Treatment of Tardive Syndrome
April 20, 2018   

The American Academy of Neurology (AAN) has released updated recommendations for treatment of tardive syndromes...
 Continue reading (Members only)
Early Intervention Service for Psychosis May Reduce Suicide in Patients with Schizophrenia
April 13, 2018   

The suicide rate among patients with schizophrenia-spectrum disorders is significantly increased compared to the general population, especially during the first episode of psychosis...
 Continue reading (Members only)
Review: Benefits vs. Risks of Aripiprazole During Pregnancy
February 7, 2018   

A systematic literature search and review evaluated the available data on the use of aripiprazole during pregnancy, peripartum and lactation...
 Continue reading
FDA Approves Pill That Digitally Tracks Adherence
November 13, 2017   

The US Food and Drug Administration (FDA), recently approved the first drug in the U.S. with a digital ingestion tracking system...
 Continue reading
Antipsychotic Use in Intellectually Disabled Adults
September 1, 2017   

Antipsychotic medication is frequently being prescribed to individuals with intellectual and developmental disabilities (IDD), often without a psychiatric diagnosis...
 Continue reading
Deutetrabenazine Approved to Treat Tardive Dyskinesia
August 30, 2017   

The U.S. Food and Drug Administration (FDA) has approved deutetrabenazine, trade name Austedo, for the treatment of tardive dyskinesia...
 Continue reading
Non-Dopaminergic Drug Shows Efficacy in Reducing Negative Symptoms of Schizophrenia
August 13, 2017   

A recent study examined the efficacy, safety, and tolerability of the compound, MIN-101 compared to placebo in patients with schizophrenia...
 Continue reading (Members only)
Top of Page